Abstract 203P
Background
The interaction between the immune system and the tumor microenvironment significantly impacts cancer progression and treatment response. Macrophages, with their diverse functional states, play a crucial role in this interplay. Identifying accurate markers for macrophage infiltration is vital for understanding their roles and therapeutic potential.
Methods
Immunai addresses this challenge by developing single cell atlases. Employing state-of-the-art single cell RNA sequencing (scRNA-seq) technologies, Immunai generates comprehensive and high-resolution transcriptomics data from diverse tumor samples, encompassing a wide range of cancer types. The establishment of scRNA-seq data atlases and references enables the identification of distinct macrophage populations within the tumor microenvironment, as well as their heterogeneity and functional states. Utilizing advanced computational algorithms and analytical pipelines, Immunai systematically analyses scRNA-seq datasets to uncover specific molecular signatures associated with macrophage infiltration.
Results
In the presented work, Immunai's approach enabled the discovery of novel macrophage-specific markers that can serve as valuable tools for both basic research and clinical applications. The identified markers offer insights into the dynamic nature of macrophage populations within the tumor microenvironment and provide potential avenues for the development of immunotherapies targeting tumor-associated macrophages. Moreover, these markers hold promise as diagnostic and prognostic indicators, aiding in patient stratification and personalized treatment strategies.
Conclusions
Immunai's approach provides a significant contribution to immuno-oncology and novel therapeutic approaches.
Legal entity responsible for the study
Immunai.
Funding
Immunai.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display